Jim Simons Vyne Therapeutics Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $4.91 $7,461 - $305,289	-62,177 Reduced 6.69%	866,827 $130,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $4.27 $2,525 - $44,933	-10,523 Reduced 1.12%	929,004 $207,000
Q2 2022 Aug 12, 2022	SELL	$0.37 - $0.71 $9,461 - $18,155	-25,571 Reduced 2.65%	939,527 $365,000
Q1 2022 May 13, 2022	BUY	$0.5 - $1.15 $30,283 - $69,652	60,567 Added 6.7%	965,098 $627,000
Q4 2021 Feb 11, 2022	SELL	$0.91 - $1.5 $309,851 - $510,744	-340,496 Reduced 27.35%	904,531 $923,000
Q3 2021 Nov 12, 2021	BUY	$1.39 - $3.47 $1.3 Million - $3.24 Million	934,100 Added 300.42%	1,245,027 $1.73 Million
Q2 2021 Aug 13, 2021	BUY	$3.24 - $6.92 $1.01 Million - $2.15 Million	310,927 New	310,927 $1.09 Million

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $170M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.